#1 Quant Ranked Health Care Stock – CNC (Centene Corporation)

Centene Corporation is a U.S. managed care company serving underinsured individuals and families as well as commercial customers.

• What does the company do?

• Why Some Investors Are Bullish

• What Bears Are Worried About

• Why the Quants like this stock

• My View

• Quick Links

---

What does the company do?

Centene Corporation is a U.S. managed care company serving underinsured individuals and families as well as commercial customers. Its businesses span Medicaid, Medicare, Commercial, and Other, providing health insurance and healthcare services including Medicaid and Medicare plans, Marketplace coverage, pharmacy, behavioral health, vision, and dental services. Founded in 1984, Centene is headquartered in St. Louis, Missouri.

---

Why Some Investors Are Bullish

• Strong Q2 earnings and return to profitability. Centene reported Q2 adjusted diluted EPS of $2.51, compared with a loss of $0.16 per share a year earlier, while GAAP diluted EPS was $2.19. The company also reported adjusted net earnings of approximately $1.2 billion, representing a substantial improvement from the year-ago period.

• Revenue continued to grow. Second-quarter total revenue increased approximately 10% year over year to $53.6 billion, while premium and service revenue rose 4% to $44.4 billion. Growth was supported by higher premium yields, rate increases in Marketplace and Medicaid, state-directed payments, and expansion of the Medicare Prescription Drug Plan business.

• Medical-cost performance improved significantly. Centene’s consolidated health benefits ratio (HBR) improved to 89.6% from 93.0% a year earlier, indicating that a smaller percentage of premium revenue was being consumed by medical costs. The improvement reflected better Marketplace pricing and risk adjustment, higher rates and improved medical-cost management in Medicaid, and favorable developments in Medicare.

• Management significantly raised its 2026 outlook. Centene increased its 2026 adjusted EPS guidance to greater than $4.80, up from its previous outlook of greater than $3.40. Management said the increase reflected underlying business strength, although approximately $0.50 of the improvement was attributable to non-recurring items in the Medicare and Commercial businesses.

• Cash flow and balance-sheet metrics improved. Centene generated approximately $3.6 billion of operating cash flow in Q2 and $8.0 billion during the first six months of 2026. Its debt-to-capitalization ratio improved to 41.6% from 46.5% at year-end 2025, and the company repurchased $260 million of senior notes during the quarter.

---

What Bears Are Worried About

• Membership has declined substantially. Total at-risk membership fell to 25.9 million from 28.0 million a year earlier, a decline of roughly 2.1 million members, or 7.6%. The largest decline was in Marketplace membership, which fell from 5.86 million to 3.49 million, while Medicaid membership also declined.

• Some of the earnings improvement is not recurring. The headline EPS improvement is impressive, but investors should distinguish between underlying earnings growth and one-time benefits. Management specifically identified approximately $0.50 of non-recurring items within the factors supporting the higher 2026 outlook.

• The business still faces medical-cost and mix-related risks. Although the consolidated HBR improved substantially, medical-cost trends remain an important variable, particularly in Medicaid and Medicare. Commercial premium and service revenue declined 7% year over year, largely reflecting lower Marketplace membership, leaving Centene exposed to changes in enrollment, pricing, risk adjustment and government healthcare policy.

---

Why the Quants like this stock

P/E Non-GAAP (FWD) B+ 12.9
Revenue Growth (YoY) B- 12.94%
EPS FWD Long Term Growth (3-5Y CAGR) A+ 38.21%
6M Price Performance A 79.41%
FY1 Up Revisions (last 90 days) 21 Up & 0 Down

Latest Quarter’s Earnings
Announce Date 7/28/2026
EPS GAAP Actual $2.19 (Beat by $1.43)
EPS Normalized Actual $2.51 (Beat by $1.43)
Revenue Actual $53.58B
Revenue Surprise Beat by $6.13B

---

My View

Centene’s Q2 report showed meaningful operational improvement, particularly in profitability, medical-cost management, cash flow and full-year guidance. The major question for investors is whether these improvements can be sustained while the company works through significant membership declines and the changing economics of its Marketplace and government-sponsored businesses.

---

Quick Links

See Comments.

All content on this site is for informational purposes only and does not constitute financial advice. Consult relevant financial professionals in your country of residence to get personalized advice before you make any trading or investing decisions. This post was written with the assistance of artificial intelligence. The original ideas and final review are human-generated.